UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling
NCT ID: NCT00355758
Last Updated: 2010-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
200 participants
OBSERVATIONAL
2005-04-30
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Urine Tests for Prostate Cancer
NCT00581516
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
NCT03354416
Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer
NCT00045331
Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
NCT00581503
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
NCT00773773
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men 50 years of age or older.
* Serum PSA greater than or equal to 2.5 ng/ml and less then or equal to 10.0 ng/ml determined by a measurement within the past six months, and/or digital rectal exam suspicious for prostate cancer as determined by the patient's Urologist.
* It has been determined by the treating physician that a prostate biopsy is clinically indicated.
* Patients will have already been diagnosed with prostate cancer and scheduled for a radical prostatectomy.
For study on treatment effect
* Men with clinically localized prostate cancer (total PSA \< 20 ng/ml and clinical T2b or less).
* Men with organ confined prostate cancer as determined by final pathologic diagnosis.
Exclusion Criteria
* Acute prostatitis.
* Untreated urinary tract infection.
* Presence of Foley catheter or any urethral instrumentation in the previous 48 hours.
* Hormonal therapies including LHRH agonists, oral anti-androgens, estrogenic compounds, Proscar or any phytotherapies within the previous 6 months.
* Men with non-organ confined prostate cancer.
* Men with detectable serum PSA levels more than 1 months following radical prostatectomy.
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Irvine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of California, Irvine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Atreaya Dash, MD
Role: PRINCIPAL_INVESTIGATOR
University of California
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Irvine
Orange, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004-3561
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.